Staci Burleyson
Payments from drug & device makers
Across 233 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$885
- AstraZeneca$672
- Otsuka America Pharmaceutical, Inc.$330
- AbbVie$238
- Lilly USA, LLC$204
- GSK$198
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,137100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$106
How this compares
$4,137 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 126 | $115,629 |
| MounjaroTirzepatide | 88 | $102,402 |
| OzempicSemaglutide | 39 | $42,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $35,770 |
| JardianceEmpagliflozin | 26 | $31,469 |
| TrulicityDulaglutide | 25 | $30,509 |
| RexultiBrexpiprazole | 16 | $24,136 |
| JanuviaSitagliptin Phosphate | 30 | $17,654 |
| EliquisApixaban | 22 | $16,292 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $15,168 |
| Repatha SureclickEvolocumab | 17 | $13,897 |
| MyrbetriqMirabegron | 16 | $9,951 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $6,229 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,135 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $204 | $132,911113 claims |
| AstraZenecaFarxiga, Symbicort | $672 | $121,858152 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $198 | $57,07266 claims |
| Novo NordiskOzempic | $885 | $42,95439 claims |
| Boehringer IngelheimJardiance | $40 | $31,46926 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $330 | $24,13616 claims |
| MerckJanuvia | $43 | $17,65430 claims |
| PfizerEliquis | $31 | $16,29222 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $9,95116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.
Other family in Salem
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.